GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Zealthy and Ro both offer FDA-approved, generic GLP-1s at personalized dosages to fit your needs. These platforms also have a ...

Mounjaro was approved by the FDA in May ... which it will compete with Novo Nordisk's fast-growing Wegovy brand of semaglutide. Assuming all goes to Lilly's plan, analysts at EvaluatePharma ...